The finding of mutations of KIT in gastrointestinal stromal tumors (GISTs) and subsequent development of kinase-directed therapy in metastatic GIST serve as a touchstone for the translation of laboratory research into clinical therapeutics. A variety of novel developments have followed the discovery of clinical activity of kinase-directed therapy against GIST. Radiological assessment of GIST challenges the standard of care for assessing tumor responses, ie, Response Evaluation Criteria in Solid Tumors (RECIST). Furthermore, the determination of the relationship of specific KIT mutations and sensitivity and resistance to kinase-directed agents and the assessment of inhibitor levels and the quality of response to those agents have implications beyond the treatment of sarcomas. These discoveries and the next chapters in this developing story are discussed in this review.

Hypericum perforatum extract, ab 1010, antineoplastic agent, article, cancer chemotherapy, cancer recurrence, cancer resistance, cancer survival, chronic myeloid leukemia, clinical trial, computer assisted tomography, contrast medium, cpg 74588, dasatinib, drug absorption, drug binding, drug blood level, drug dose comparison, drug efficacy, drug mechanism, drug sensitivity, fluorodeoxyglucose f 18, gastrointestinal stromal tumor, gene mutation, human, imatinib, ketoconazole, masitinib, medical assessment, metastasis, midostaurin, motesanib, nilotinib, osi 930, pazopanib, positron emission tomography, priority journal, protein tyrosine kinase inhibitor, rifampicin, sarcoma, sorafenib, stem cell factor, sunitinib, treatment outcome, treatment response, unclassified drug, vatalanib, xl 820,
Seminars in Oncology
Erasmus MC: University Medical Center Rotterdam

Benjamin, R.S, Debiec-Rychter, M, le Cesne, A, Sleijfer, S, Demetri, G.D, Joensuu, H, … Poveda, A. (2009). Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment. Seminars in Oncology, 36(4), 302–311. doi:10.1053/j.seminoncol.2009.06.003